中国药房2025，Vol.36Issue(18)：2262-2266,5.DOI:10.6039/j.issn.1001-0408.2025.18.08
基于HPLC指纹图谱和有效成分含量评价不同产地草豆蔻质量
Evaluation of the quality of Alpinia katsumadai from different habitats based on HPLC fingerprint and determination of active ingredient content
摘要
Abstract
OBJECTIVE To evaluate the quality differences of Alpinia katsumadai from different habitats.METHODS High-performance liquid chromatography(HPLC)was used to establish the fingerprints of A.katsumadai from 18 batches of different habitats,and the quality of A.katsumadai from different habitats was comprehensively evaluated by similarity evaluation,cluster analysis(CA),principal component analysis(PCA),orthogonal partial least squares-discriminant analysis(OPLS-DA)and the content determination results of alpinetin,pinocembrin,cardamonin and alnustone in A.katsumadai.RESULTS The similarity of HPLC fingerprints for 18 batches of A.katsumadai was＞0.9.Eleven common peaks were identified from the chromatogram,and four of them were specifically characterized.Both CA and PCA grouped 18 batches of A.katsumadai into 3 categories,extracting 2 principal components(the cumulative variance contribution rate reached 89.798%).OPLS-DA identified 9 quality difference markers,namely the components corresponding to peaks 4,9,3,2,7(pinocembrin),8(cardamonin),6(alpinetin),10 and 11(alnustone).The content of alpinetin,pinocembrin,cardamonin,and alnustone ranged from 4.507 1-11.579 7,5.154 4-14.183 3,5.109 5-13.588 3 and 4.494 6-11.277 2 mg/g,respectively.CONCLUSIONS The quality of A.katsumadai from different habitats is quite different,and the quality of A.katsumadai from Hainan is the best.关键词
草豆蔻/HPLC指纹图谱/化学模式识别/含量测定/产地/质量控制Key words
Alpinia katsumadai/HPLC fingerprint/chemical pattern recognition/content determination/habitats/quality control分类
医药卫生引用本文复制引用
廖延武,汪英俊,刘顺,邱明鸣,朱育凤..基于HPLC指纹图谱和有效成分含量评价不同产地草豆蔻质量[J].中国药房,2025,36(18):2262-2266,5.基金项目
江苏省基础研究计划面上项目(No.BK20211395) （No.BK20211395）
江苏省中医院院级课题(No.Y22036) （No.Y22036）
江苏省中医疫病研究中心开放课题(No.JSYB2024KF11) （No.JSYB2024KF11）
江苏省药学会-奥赛康医院药学基金立项课题(No.A202103) （No.A202103）
